Comparing Prourocare Medical (PUMD) and T2 Biosystems (TTOO)

Prourocare Medical (OTCMKTS:PUMD) and T2 Biosystems (NASDAQ:TTOO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, institutional ownership and valuation.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Prourocare Medical and T2 Biosystems, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prourocare Medical 0 0 0 0 N/A
T2 Biosystems 0 1 4 0 2.80

T2 Biosystems has a consensus target price of $10.07, suggesting a potential upside of 126.22%. Given T2 Biosystems’ higher possible upside, analysts clearly believe T2 Biosystems is more favorable than Prourocare Medical.

Insider & Institutional Ownership

56.3% of T2 Biosystems shares are owned by institutional investors. 29.3% of Prourocare Medical shares are owned by insiders. Comparatively, 31.5% of T2 Biosystems shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Prourocare Medical has a beta of 8.37, meaning that its share price is 737% more volatile than the S&P 500. Comparatively, T2 Biosystems has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500.

Profitability

This table compares Prourocare Medical and T2 Biosystems’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Prourocare Medical N/A N/A N/A
T2 Biosystems -522.30% -461.31% -84.34%

Valuation and Earnings

This table compares Prourocare Medical and T2 Biosystems’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Prourocare Medical N/A N/A N/A N/A N/A
T2 Biosystems $4.66 million 42.06 -$62.42 million N/A N/A

Prourocare Medical has higher earnings, but lower revenue than T2 Biosystems.

Summary

T2 Biosystems beats Prourocare Medical on 5 of the 9 factors compared between the two stocks.

Prourocare Medical Company Profile

ProUroCare Medical Inc. engages in developing products for the detection and characterization of male urological prostate disease. It offers the ProUroScan System, a prostate imaging system that aids the physician in documenting abnormalities in the prostate that have been previously detected by a digital rectal exam. The company has licensing, development, and commercialization agreements with Artann Laboratories Inc. for its ProUroScan System. ProUroCare Medical Inc. was founded in 1999 and is based in Eden Prairie, Minnesota.

T2 Biosystems Company Profile

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company also offers T2Dx, a bench-top instrument for sepsis, Lyme disease, and other applications, as well as T2Candida panel for the detection of candida species in human whole blood specimens. In addition, it is developing T2Bacteria, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; T2Lyme for the detection of various strains of Lyme disease-causing bacteria; and T2Plex, an integrated instrument for hemostasis applications. The company has collaboration agreement with Canon U.S. Life Sciences, Inc. to develop a novel diagnostic test panel to detect Lyme disease; and Allergan Sales, LLC for the direct detection diagnostic test panel that adds additional bacteria species to the existing T2Bacteria product candidate and testing drug resistance directly in whole blood. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.

Receive News & Ratings for Prourocare Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prourocare Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply